Protecting Truth in the Digital Age
We monitor, analyze, and combat disinformation to preserve the integrity of public discourse.
Top Articles
As summer temperatures climb and the sun’s rays grow stronger, the conversation around skincare invariably pivots to sunscreen. However, over the past few years, social media platforms like TikTok have become breeding grounds for a dangerous wave of misinformation regarding UV protection. From “sunscreen shaming”—the idea that chemical filters are…
Editor's Picks
The pharmaceutical industry is currently witnessing a fierce battle between two corporate giants, Novo Nordisk and Eli Lilly, as they aggressively vie for market dominance in the multi-billion-dollar weight-loss drug sector. Novo Nordisk, the manufacturer of the blockbuster medication Ozempic, has recently leveled serious accusations against Eli Lilly, claiming the company engaged in false and misleading advertising. At the heart of the dispute is the marketing of Mounjaro, an Eli Lilly drug originally developed for type 2 diabetes that has rapidly gained popularity as a potent weight-loss treatment. Novo Nordisk argues that certain promotional materials disseminated by their competitor have…
Ahead of the critical Special Meeting on July 30, 2026, XA Investments (XAI) is reaching out directly to shareholders of the XAI Floating Rate & Alternative Income Trust (XFLT) to set the record straight. Kimberly Flynn, President of XAI, has released a series of videos aimed at countering recent misleading claims made by Octagon Credit Investors, the trust’s former sub-adviser. The core of the matter involves a decisive shift in leadership; the Board of Directors has unanimously recommended that shareholders vote “FOR” the transition to a new investment sub-adviser: Rockford Tower Asset Management, a subsidiary of the global firm King…
